Practical Model-Based Dose Finding in Early-Phase Clinical Trials: Optimizing Tissue Plasminogen Activator Dose for Treatment of Ischemic Stroke in Children

Stroke - United States
doi 10.1161/strokeaha.107.510164
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Low-Dose Versus Standard-Dose Tissue Plasminogen Activator for Intravenous Thrombolysis in Asian Acute Ischemic Stroke Patients

Stroke
CardiologyNeurologyCardiovascular MedicineAdvancedMedicineNeuroscienceSpecialized Nursing
2010English

Tissue Plasminogen Activator-Based Nanothrombolysis for Ischemic Stroke

Expert Opinion on Drug Delivery
Pharmaceutical Science
2017English

Low-Dose Tissue Plasminogen Activator for Calciphylaxis

Archives of Dermatology
2004English

Early Changes of Tissue Perfusion After Tissue Plasminogen Activator in Hyperacute Ischemic Stroke

Stroke
CardiologyNeurologyCardiovascular MedicineAdvancedMedicineNeuroscienceSpecialized Nursing
2011English

Genome Response to Tissue Plasminogen Activator in Experimental Ischemic Stroke

BMC Genomics
BiotechnologyGenetics
2010English

A Dose-Schedule Finding Design for Phase I-Ii Clinical Trials

Journal of the Royal Statistical Society. Series C: Applied Statistics
UncertaintyStatisticsProbability
2015English

Angioedema Secondary to IV Tissue Plasminogen Activator Administration for Treatment of Acute Ischemic Stroke

Case Reports in Critical Care
2018English

Systemic Review : Role of Tissue Plasminogen Activator for Acute Ischemic Stroke

The Egyptian Journal of Hospital Medicine
2018English

Adaptive Dose Finding Based Ont-Statistic for Dose–response Trials

Statistics in Medicine
EpidemiologyStatisticsProbability
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy